Innovation Pharmaceuticals Inc (IPIX)

[frrol]

No, it doesn't. It takes a pharma interested in doing a licensing deal with the company, and this is what we're trying to get to. There's no secret handshake either.

It's likely tough for a pharma licensing team to get approval to make an offer for an indication like S-OM for a Phase 2 drug that was turned down for BTD. Not impossible, but tough; there is a deep clinical need and the FDA says they're not impressed enough with the results to expedite it. (Yes B has general FT, but that is moot on several levels. The time we lost from funding delay blew that out of the water in time and equity unfortunately. B-ABSSSI itself will not receive any effective short cuts on Phase 3.)